Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8351187 | 0.84 | USP2 (0.46) | OPRM1HSD11B1SIGMAR1MEN1KMT2A | |
| SCHEMBL8351183 | 0.83 | HPGD (0.46) | OPRM1HSD11B1SIGMAR1MEN1KMT2A | |
| SCHEMBL8351554 | 0.80 | USP2 (0.45) | OPRM1HSD11B1SIGMAR1MEN1KMT2A | |
| SCHEMBL8353497 | 0.80 | USP2 (0.45) | OPRM1HSD11B1SIGMAR1MEN1KMT2A | |
| SCHEMBL14347920 | 0.79 | MEN1 (0.58) | HSD11B1SIGMAR1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL16523027 | 0.79 | HSD11B1 (0.62) | OPRM1HSD11B1SIGMAR1LMNA | |
| SCHEMBL16507031 | 0.78 | KMT2A (0.56) | HSD11B1SIGMAR1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL19242638 | 0.78 | KMT2A (0.60) | HSD11B1SIGMAR1CYP1A2CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL16507430 | 0.77 | MAPK1 (0.58) | OPRM1HSD11B1SIGMAR1CYP1A2CYP2D6 | |
| SCHEMBL3139523 | 0.76 | HSD11B1 (0.71) | HSD11B1CYP2C9MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312214-B2 | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1505966-A4 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1505966-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | disclosed |
| WO-2003099276-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | SERPINC1, PCSK9, PLAT | OPRM1 4713/4885HSD11B1 474/4885SIGMAR1 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.